Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 9/20 | 0.65 |
| ▸ | MMP13 | P45452 | 7/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
| ▸ | MMP14 | P50281 | 1/20 | 0.62 |
| ▸ | PTGFR | P43088 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613430 | 0.95 | MMP12 (0.72) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL28009962 | 0.91 | MMP12 (0.55) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL11221992 | 0.85 | LDHA (0.53) | MMP12MMP13MMP2MMP9LDHA | |
| SCHEMBL7277594 | 0.84 | HTT (0.56) | PTGFRALDH1A1F2RL1 | |
| SCHEMBL6462909 | 0.83 | LDHA (0.64) | MMP2MMP9LDHAFFAR1POLB | |
| SCHEMBL5365699 | 0.83 | S1PR2 (0.62) | MMP12MMP2MMP9LDHAFFAR1 | |
| SCHEMBL6462808 | 0.83 | FFAR1 (0.50) | MMP12MMP13MMP2MMP9LDHA | |
| SCHEMBL6464896 | 0.83 | FFAR1 (0.50) | MMP12MMP13MMP2MMP9LDHA | |
| SCHEMBL5613402 | 0.83 | MMP12 (0.91) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL1139059 | 0.81 | MMP12 (0.68) | MMP12MMP13MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | MMP12 132/4885MMP13 49/4885MMP2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.